source
- Industry urges FDA to broaden prior-knowledge guidance for gene and cell therapiesIndustry stakeholders have asked the U.S. Food and Drug Administration to expand the scope of its recent draft guidance on scientifically valid prior knowledge for gene therapies that involve genom…
- Mass General Brigham drops Dana-Farber from its Medicare Advantage network starting Oct 1Mass General Brigham announced that its Medicare Advantage plan will no longer include Dana-Farber Cancer Institute in its provider network beginning October 1, following a recent split between the…